ASB9

ASB9 is the substrate-recognition subunit of an ECS-type Cullin 5 RING E3 ubiquitin ligase that selects diverse substrates through its ankyrin repeat domain and recruits the catalytic core via its SOCS box, thereby controlling the proteasomal turnover of metabolic, transcriptional, and chromatin-associated targets (PMID:17148442, PMID:23837592). The ankyrin repeats engage substrates such as cytosolic creatine kinase B (CKB) and ubiquitous mitochondrial creatine kinase (uMtCK) in a SOCS box-independent manner, while the SOCS box drives substrate degradation; full-length ASB9 ubiquitylates uMtCK, disrupts mitochondrial structure, lowers membrane potential, and reduces creatine kinase activity (PMID:17148442, PMID:20302626). ASB9 is unstable alone but forms a stable ternary complex with Elongin B/C that binds selectively to the Cullin 5 N-terminal domain, assembling the ASB9–EloBC–CUL5–RBX2 ligase (PMID:23837592). Structural and HDX-MS studies show that ASB9 binds creatine kinase with very high affinity and that ASB9 and CUL5 behave as rigid rods joined by an EloB/C hinge, transmitting long-range allosteric signals from the bound substrate to the RBX2 E2-recruiting region to enable dynamic ubiquitin transfer across the complex (PMID:25654263, PMID:32513959). The ligase polyubiquitylates free histones H3 and H4 — but not H2A/H2B, nucleosomal histones, or Asf1-bound histones — generating K48 and K63 chains, and does so without requiring an ARIH2 RBR helper ligase, distinguishing it from other CUL5 complexes (PMID:41260500). Physiologically, ASB9 suppresses ovarian granulosa cell proliferation and apoptosis through MAPK signaling and is itself transcriptionally induced by CLOCK (PMID:34476862, PMID:37280645), restrains spermatogonial stem cell proliferation by degrading HIF1AN (PMID:36683111), and assembles a testis-specific TNP2-targeting CRL whose loss causes TNP2 retention, failed histone-to-protamine transition, and male infertility in mice and humans (PMID:41915740).

1. 2006 High

   Established ASB9 as a substrate receptor of an E3 ubiquitin ligase by identifying its first target and showing degradation depends on the SOCS box, defining the bipartite logic of substrate binding versus degradation.

   Evidence Proteomics/pull-down, Co-IP, ubiquitination assay, and cellular protein-level measurement of CKB

   PMID:17148442

   Open questions at the time

   • Did not identify the Cullin/Elongin core recruited by the SOCS box
   • Physiological context of CKB regulation untested
2. 2010 High

   Extended ASB9 targeting to mitochondrial uMtCK and linked its E3 activity to functional consequences for mitochondrial integrity and creatine kinase activity, using a naturally occurring SOCS-deleted variant as a degradation-deficient control.

   Evidence Co-IP, confocal co-localization, ubiquitination and mitochondrial membrane potential/CK activity assays comparing ASB9 vs ASB9ΔSOCS

   PMID:20302626

   Open questions at the time

   • In vivo relevance of mitochondrial CK regulation not addressed
   • Tissue specificity of uMtCK targeting unknown
3. 2012 High

   Defined the structural basis of substrate recognition by solving the ASB9 ankyrin domain and mapping the CKB-binding determinants, showing which repeats and residues mediate target engagement.

   Evidence X-ray crystallography at 2.2 Å, mutagenesis (His103/Phe107), and truncation binding assays

   PMID:22418839

   Open questions at the time

   • Structure of full ligase complex not determined
   • Did not address how substrate binding couples to ubiquitin transfer
4. 2013 High

   Resolved how the unstable ASB9 receptor is stabilized and which Cullin scaffold it recruits, establishing selective CUL5 over CUL2 engagement that defines the complex as an ECS-type CRL.

   Evidence DSF, ITC, native and ion-mobility mass spectrometry, and molecular modeling of ASB9–EloBC–Cul5NTD assembly

   PMID:23837592

   Open questions at the time

   • Did not visualize the catalytic RBX2/E2 arm
   • Did not connect assembly to ubiquitin transfer geometry
5. 2015 High

   Quantified the ASB9–creatine kinase interface and revealed that ASB9 not only targets but partially inhibits CK enzymatic activity, adding a non-degradative regulatory dimension to its function.

   Evidence HDX-MS interface mapping, enzymatic activity assays, mutagenesis, and binding affinity measurements with deletion constructs

   PMID:25654263

   Open questions at the time

   • Whether enzymatic inhibition occurs independent of degradation in cells untested
   • Stoichiometry within full CRL not addressed
6. 2016 Medium

   Built an atomic model of the full CK-targeting CRL and proposed a dynamic motion-based mechanism allowing ubiquitin to reach the substrate across ~60 Å, framing ligase function as conformationally driven.

   Evidence Integrative modeling, SAXS, and normal-mode analysis

   PMID:27396830

   Open questions at the time

   • Computational model not validated by experimental structure at the time
   • Allosteric coupling not directly demonstrated
7. 2020 High

   Provided experimental structures and HDX-MS evidence that ASB9 and CUL5 act as rigid rods hinged at EloB/C, demonstrating long-range allosteric signaling from substrate to the RBX2 catalytic linker and revising the mechanistic model of CUL-E3 ligases.

   Evidence Cryo-EM of CKB–ASB9–ELOB/C and full-length CUL5–RBX2, combined with HDX-MS and integrative modeling

   PMID:32513959

   Open questions at the time

   • Allosteric pathway not dissected by point mutations
   • Whether allostery generalizes to non-CK substrates untested
8. 2019 Medium

   Identified cell-type-specific ASB9 partners (PAR1, TAOK1, TNFAIP6) in granulosa cells and showed ASB9 suppresses their proliferation, while documenting that the canonical CKB interaction is absent in this context, indicating context-dependent substrate selection.

   Evidence Yeast two-hybrid screen and CRISPR/Cas9 inhibition with proliferation and gene-expression readouts in ovarian granulosa cells

   PMID:30811458

   Open questions at the time

   • Y2H partners not confirmed as ubiquitylation substrates
   • Single lab; reciprocal validation lacking
9. 2021 Medium

   Placed ASB9 upstream as a negative regulator of MAPK signaling in granulosa cells, linking its loss to reduced apoptosis and increased proliferation and connecting it to the ovulatory hCG response in vivo.

   Evidence CRISPR/Cas9 inhibition with apoptosis markers, phospho-MAPK3/1 western blot, and an in vivo hCG model

   PMID:34476862

   Open questions at the time

   • Direct substrate linking ASB9 to MAPK not identified
   • Single lab, single study
10. 2023 Medium

    Defined HIF1AN as the functional ASB9 target in spermatogonial stem cells through a rescue experiment, and showed CLOCK transcriptionally activates ASB9, embedding it in upstream and downstream regulatory circuits in reproductive tissues.

    Evidence Co-IP and HIF1AN re-expression rescue in an SSC line; CLOCK E-box promoter binding and proliferation assays in granulosa cells

    PMID:36683111 PMID:37280645

    Open questions at the time

    • HIF1AN ubiquitylation/degradation by ASB9 not directly shown in these studies
    • CKB again absent as a partner, leaving context-specificity rules unresolved
11. 2025 High

    Demonstrated that the reconstituted ASB9-CRL5 polyubiquitylates free histones H3/H4 with strict substrate-context specificity and does so without an ARIH2 helper ligase, the first such example for CUL5 complexes.

    Evidence In vitro reconstituted ubiquitylation, binding affinity measurements, lysine-site mapping, chain-type analysis, and nucleosome/Asf1 competition assays

    PMID:41260500

    Open questions at the time

    • Cellular role of free histone degradation by ASB9 not established
    • Mechanism replacing ARIH2 function not defined
12. 2026 High

    Established a physiological, in vivo role for ASB9 in spermiogenesis by showing it assembles a testis-specific TNP2-targeting CRL whose loss causes failed histone-to-protamine transition and male infertility in mice and humans.

    Evidence Co-IP for complex assembly, mouse and human loss-of-function genetics, ubiquitination assays, and spermiogenesis/fertility phenotyping

    PMID:41915740

    Open questions at the time

    • Uses RBX1 rather than RBX2 — how core composition is selected unclear
    • Relationship between TNP2 degradation and the free-histone ubiquitylation activity not integrated

• How ASB9 selects among its many substrates in a tissue-specific manner, and which physiological program governs whether it targets metabolic enzymes, transcriptional regulators, or chromatin components, remains unresolved.
• No unifying model for context-dependent substrate choice
• Cellular significance of free histone ubiquitylation unknown
• Determinants of RBX1 vs RBX2 and core variation undefined